Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain ...
Cancer patients have often organized support and informational groups around their disease types. Now a presentation at the American Association for Cancer Research (AACR) Annual Meeting 2018 ...
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that, based on recent FDA guidance, Ignyta has completed ...
In 67 ROS1 TKI-naïve patients, the confirmed objective response rate (cORR) and disease control rate (DCR) were 92.5% and 95.5%, respectively. In 38 crizotinib-pretreated patients, the cORR and DCR ...
Zidesamtinib achieved a 44% ORR and 1% CR rate in advanced ROS1-positive NSCLC patients previously treated with ROS1 TKIs. The ARROS-1 trial showed zidesamtinib's efficacy, especially in patients with ...
Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-520 of 100 mg daily NVL-520 is a novel brain-penetrant ROS1-selective tyrosine kinase inhibitor (TKI) created with ...
A new study shows that three common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be ...
A woman with metastatic lung adenocarcinoma harboring a ROS1 rearrangement initially showed a response to treatment with crizotinib, but the disease ultimately progressed. In her resistant tumors, we ...
Drugs like crizotinib are used to treat patients with ROS1-positive lung cancer. But which patients are ROS1-positive? A University of Colorado Cancer Center study published in the Journal of Thoracic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results